Amgen USA Inc — Federal Contractor Profile

AMGEN USA INC Secures Billions in Government Contracts for Biopharmaceutical Solutions

Contractor Overview

Total Contract Value: $188,052,598,584 ($188.1B)

Total Awards: 243

Company Profile

AMGEN USA INC is a prominent biopharmaceutical company with a significant footprint in government contracting, primarily focused on the research, development, and provision of innovative medicines and biological products. Their core capabilities lie in advanced biotechnology, drug discovery, clinical trials, and the manufacturing of complex therapeutics, particularly in areas like oncology, immunology, cardiovascular disease, and bone health. While specific agency clients are not detailed in the provided data, AMGEN's work likely supports federal health agencies such as the Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), as well as the Department of Defense (DoD) for medical readiness and veteran healthcare. The scale of AMGEN's government business is substantial, evidenced by a total contract value of $13.93 billion across 18 contracts, with an exceptionally high average contract size of over $773 million. This suggests a focus on large-scale, long-term agreements, likely for the supply of critical pharmaceuticals or significant research initiatives. The limited data on recent contracts and the absence of specific agency client information make it difficult to ascertain their win patterns (competitive vs. sole-source) or track record on specific projects. However, the sheer volume and average size of their contracts indicate a strategic focus on high-value, complex procurements, positioning them as a key supplier for government healthcare and research needs. Their business strategy appears geared towards securing major, enduring contracts rather than a high volume of smaller awards.

Specializations

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: N/A

Agency Concentration: N/A

Growth Trajectory: N/A

Competitive Position

AMGEN USA INC operates as a major player in the biopharmaceutical sector, likely holding a dominant position in supplying specialized, high-cost therapeutics to government entities. Their substantial contract values suggest they are a preferred provider for complex biological products and advanced research, potentially facing competition from other large pharmaceutical and biotechnology firms. Their ability to secure such large contracts indicates strong technical capabilities and established relationships within the healthcare procurement landscape.

Value to Taxpayers

The significant value of AMGEN's contracts suggests they are providing essential, high-demand biopharmaceutical products or services to the government. The large average contract size implies efficiency in delivering these complex solutions at scale. Without more data on competitive bidding and performance metrics, a definitive assessment of value is challenging, but the scale of their involvement points to a critical role in government health initiatives.

Agency Relationships

While specific agencies are not listed, AMGEN's biopharmaceutical focus strongly suggests reliance from federal health bodies like HHS (including NIH, FDA) for drug procurement, research grants, and regulatory support. The Department of Defense may also be a significant client for medical supplies and research. Dependency risks could arise if AMGEN is a sole or primary supplier for critical medications, impacting government continuity of care.

Red Flags

Green Flags

Key Contracts

The provided data for AMGEN USA INC highlights a substantial government contracting presence, totaling $13.93 billion across 18 contracts. The most striking metric is the average contract size, which stands at an impressive $773,879,007. This figure indicates that AMGEN is not engaged in numerous small-scale procurements but rather secures a few, very large, and likely long-term agreements. These substantial contracts suggest a focus on high-value, complex biopharmaceutical products or services that require significant investment and specialized expertise. Such large awards are typically for the supply of critical medicines, advanced research and development initiatives, or comprehensive healthcare solutions that span multiple years. The nature of these contracts implies that AMGEN is a key provider for government healthcare needs, potentially supplying life-saving drugs or contributing to significant public health research endeavors. Without specific contract descriptions, it's inferred that these agreements are crucial for federal agencies responsible for public health, military medical readiness, or veteran care, underscoring AMGEN's role as a strategic partner in these vital areas.

Frequently Asked Questions

What does AMGEN USA INC do for the government?

AMGEN USA INC provides the U.S. government with advanced biopharmaceutical products and services. This includes the research, development, manufacturing, and supply of innovative medicines and biological therapies. Their work likely supports federal health initiatives, providing critical treatments for various diseases, contributing to medical research, and potentially supplying the Department of Defense with essential pharmaceuticals for service members and veterans. Their specialization in complex biologics positions them as a key partner in addressing significant public health challenges.

How much taxpayer money does AMGEN USA INC receive?

AMGEN USA INC has received a total of $13.93 billion through 18 government contracts. This substantial amount is distributed across these contracts, resulting in a very high average contract size of approximately $773.88 million per contract. This indicates a significant financial commitment from the government towards AMGEN's biopharmaceutical offerings and services.

Is AMGEN USA INC good value for taxpayer money?

Assessing the value AMGEN USA INC provides to taxpayers is challenging without detailed performance data and competitive bidding information. However, the company's ability to secure large, long-term contracts suggests it possesses the specialized capabilities and capacity to meet significant government needs in the biopharmaceutical sector. The high average contract value implies efficiency in delivering complex, high-cost products or services at scale. Further analysis of contract performance, cost-effectiveness compared to alternatives, and adherence to timelines would be necessary for a comprehensive value assessment.

How does AMGEN USA INC win its contracts?

The provided data does not specify whether AMGEN USA INC wins contracts through competitive bidding or sole-source awards. However, the extremely large average contract size ($773+ million) suggests that they likely secure major, complex procurements. These could be awarded competitively based on technical merit and price for large-scale supply agreements or research programs, or potentially through sole-source channels if they are the sole provider of a critical, patented therapeutic or possess unique, indispensable expertise.

What agencies use AMGEN USA INC most?

The provided data does not explicitly list AMGEN USA INC's top agency clients. However, given AMGEN's specialization in biopharmaceuticals, it is highly probable that agencies such as the Department of Health and Human Services (HHS), including its sub-agencies like the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), are major clients. The Department of Defense (DoD) may also be a significant user for medical supplies and research related to military personnel and veterans.

Related Pages